BEACON introduced another promising multikinase inhibitor, Lenvatinib, under the brand name of Lenvanix for global market.
Lenvatinib is an anticancer drug. It is the
- First new Front-Line treatment option for Hepatocellular Carcinoma (HCC) approved in Japan in nearly 10 years.
- First TKI to demonstrating Complete Response (CR) in a phase 3 trial for locally recurrent or metastatic, progressive RAI-refractory Differentiated Thyroid Cancer (DTC):
- Lenvatinib plus everolimus is the first and only FDA-approved regimen for advanced Renal Cell Cancer (RCC) treatment in the past decade
- Once daily oral dose
Lenvanix is an oral capsule preparation which is available in the strengths of 10mg & 4mg. Each pack of Lenvanix contains 30 capsules.
To know more visit www.Lenvanix.com